Drug
Ga(III)-DOTATOC clinical trials
Keep track of what changes. Save the Ga(III)-DOTATOC studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Written with another drug
- 68Ga-DOTATOC
- 3
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 2
Jiangsu HengRui Medicine Co., Ltd. (1) · Montefiore Medical Center (1) · University Hospital, Grenoble (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Ga(III)-DOTATOC is read from its arms, and is right about nine times in ten.
Testing it · 3
- Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast CancerRecruitingPhase 3University Hospital, GrenobleNCT06611891Written as 68Ga-DOTATOC
- Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine TumorsCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT06091748Written as 68Ga-DOTATOC
- Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT ScanCompletedPhase 3Montefiore Medical CenterNCT03136328Written as 68Ga-DOTATOC